BCM
ALXN

Bridgeway Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Bridgeway Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-20,300
Closed -$3.37M – 1533
2014
Q3 		$3.37M Buy
+20,300
New +$3.33M 0.08% 276

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bridgeway Capital Management's ALXN Position: Q4 2014 in Review

Bridgeway Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2014, closing a stake of 20,300 shares — an estimated $3.37M sold.

Bridgeway Capital Management first reported a position in ALXN in Q3 2014 and held it in 1 quarter. The position peaked at $3.37M in Q3 2014. 578 funds tracked by Wall St. Rank hold ALXN as of Q4 2014.

  • Bridgeway Capital Management reported no remaining Alexion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Bridgeway Capital Management sold 20,300 Alexion Pharmaceuticals shares in Q4 2014, an estimated $3.37M.
  • Bridgeway Capital Management first reported a position in Alexion Pharmaceuticals in Q3 2014 and held it in 1 quarter.
  • Bridgeway Capital Management's Alexion Pharmaceuticals position peaked at $3.37M in Q3 2014.
  • 578 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2014.

Based on Bridgeway Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.